Insights - Amgen’s PCSK9 inhibitor, evolucumab (AMG145) met its co-primary endpoints in a phase 3 trial: the percent reduction from baseline in low-density lipoprotein cholesterol (LDL-C) at week … Continue Reading
Read nowInsights - Raptor Pharmaceutical Corp. (RPTP) announced it has submitted an investigational new drug application (IND) to the U.S. Food and Drug Administration (FDA) for the clinical … Continue Reading
Read nowInsights - Last month, AbbVie (ABBV) reported that its new Hepatitis-C treatment was effective in 96% of patients who had never been treated for the virus. On … Continue Reading
Read nowInsights - This week’s Annual Meeting of the American Society of Hematology (ASH) will highlight new treatments, new indications, new pathways and new ways of engineering cancer-treating … Continue Reading
Read nowInsights - GlaxoSmithKline (GSK) and Theravance, Inc. (THRX) posted positive results from a phase 3 study of its combination drug, Ellipta (FF/VI), as an asthma medication. The … Continue Reading
Read nowInsights - An experimental drug from Novartis (NVS) designed to treat a bone marrow cancer met its primary goal in a phase 3 study. In an earlier … Continue Reading
Read nowInsights - Eli Lilly and Company (LLY) on Thursday said it would not seek approval for edivoxetine, an experimental drug to treat major depression, after it failed … Continue Reading
Read now
